Stock AnalizAstrana Health, Inc. ASTH
Professional Services · data as of November 13, 2026
Astrana Health, Inc. (ASTH) is a consumer discretionary company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $3.9B and net income of $53M, a net margin of 1.4%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is future growth (4/5); the weakest is financial health (1/5).
Key numbers: a P/E of 29.4, a price to free cash flow of 15.9, 5-year revenue growth of 36% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 21% above the current price.
Score: 2.6 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.9B | $3.2B | $2.0B | $1.4B | $1.1B | $774M | $687M |
| Net income | $53M | $22M | $43M | $61M | $45M | $69M | $38M |
| Free cash flow | $99M | $104M | $44M | $40M | $59M | $51M | $45M |
| EPS (diluted) | $1.08 | $0.46 | $0.90 | $1.29 | $0.99 | $1.52 | $1.01 |
| Net margin | 1.4% | 0.7% | 2.1% | 4.4% | 4.0% | 8.9% | 5.5% |
| ROIC | — | 2.5% | 4.7% | 5.8% | 7.1% | 8.9% | 9.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $51.89, 63% above the current price; targets range from $45.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $2.97 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Astrana Health’s P/E ratio?
About 29.4, based on the last twelve months of diluted earnings per share (forward P/E about 9.8).
Is Astrana Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 21% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Astrana Health pay a dividend?
Not currently.
Is Astrana Health a good stock to buy?
We do not give buy or sell advice. Astrana Health scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.